Core Insights - Clearmind Medicine Inc. has engaged a leading government and political affairs consulting firm to advance its mission of developing psychedelic-based therapeutics [1][2] - The company aims to navigate complex regulatory landscapes and promote acceptance of psychedelic therapies among U.S. policymakers [2][3] - Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for alcohol use disorder (AUD) at prestigious institutions [3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat mental health disorders such as PTSD [2] - The partnership with the consulting firm aims to educate policymakers on the therapeutic potential of psychedelics and support the development of balanced regulations [3]
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics